GILD Gilead Sciences
A formidable HIV franchise funds modest growth, but acquisition discipline and patent dependence limit forever-business appeal.
The business
Gilead develops and sells patented medicines, with most profits coming from its dominant HIV treatment franchise. It also markets therapies for liver disease, cancer, and cell therapy while reinvesting heavily in drug development and acquisitions. Cash flows depend on clinical success, regulatory approval, reimbursement, and preserving patent protection.
Quality gate · 78/100
Moat & management
| Moat | wide moat |
| Source | intangible |
| Trajectory | stable |
| Management | adequate |
Patents, virology expertise, physician trust, and a deeply established HIV franchise protect strong economics. Biktarvy's extended U.S. patent runway and lenacapavir strengthen the franchise, although patent cliffs and competing therapies prevent calling the moat permanently secure.
Debt and dividends are manageable, but capital allocation is mixed: internal HIV innovation has been excellent while several expensive oncology and diversification investments have produced disappointing returns. Share reduction has also been modest.
Owner-earnings inputs
| Owner earnings (TTM) | 10.23B |
| Owner-earnings yield | 6.3% |
| Free-cash-flow yield | 6.3% |
| Growth used (normalized) | 3.0% |
| Market-implied growth (reverse DCF) | 1.3% |
| Terminal growth | 3.0% |
| Discount rate (hurdle) | 9.0% |
Projected owner earnings
| Yr | Owner earnings | Growth | PV |
|---|---|---|---|
| 1 | 10.54B | 3.0% | 9.67B |
| 2 | 10.85B | 3.0% | 9.13B |
| 3 | 11.18B | 3.0% | 8.63B |
| 4 | 11.51B | 3.0% | 8.16B |
| 5 | 11.86B | 3.0% | 7.71B |
| 6 | 12.22B | 3.0% | 7.28B |
| 7 | 12.58B | 3.0% | 6.88B |
| 8 | 12.96B | 3.0% | 6.50B |
| 9 | 13.35B | 3.0% | 6.15B |
| 10 | 13.75B | 3.0% | 5.81B |
Key risks
- Dependence on Biktarvy and eventual HIV patent expirations
- Poor returns from costly acquisitions or unsuccessful clinical programs
- Government pricing pressure and reimbursement reform
Catalysts
- Broad adoption and indication expansion of lenacapavir-based HIV prevention and treatment
- Successful oncology launches and expanded Trodelvy indications
Recent news
score · 8 articles
- Own Regeneron For Biotech Growth? Incyte Is Making Its Case.
- Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.
- Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
- 2 Recession-Resistant Dividend Stocks to Buy and Hold
- Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?
- Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access
- Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative
- Morgan Stanley Keeps Buy Rating on Gilead (GILD)
⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Price pays for ~1%/yr owner-earnings growth over 10y (reverse DCF); model credits 3%.